PET scan comparison for liver cancer diagnosis
Part of Cancer, Digestive system clinical trials.
This trial tests whether a new PET imaging agent (GPC3-targeted) can find liver cancer as well as or better than enhanced MRI. It may help diagnose hepatocellular carcinoma (the most common type of liver cancer) more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with hepatocellular carcinoma or your doctor strongly suspects it.
- You are willing to have a biopsy (tissue sample) if you haven't already.
- You are expected to live more than 3 months.
- You can follow the study schedule and procedures.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new PET imaging method that targets GPC3, a protein often found in liver cancer cells. It may help doctors see and understand liver cancer better, especially in people with newly diagnosed or recurrent disease.
This study tests a new imaging method that uses a special substance to find liver cancer cells. It may help doctors see if the cancer has come back after treatment, which could guide next steps.
This trial tests a new imaging technique that may help doctors see liver cancer more clearly. It uses a special tracer that targets a protein found on many liver cancer cells. This could help with diagnosis and monitoring.
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
This study tests a new type of PET/CT scan (called PSMA) that may help doctors see liver cancer (HCC) better. The scan takes detailed images to track how the cancer behaves, which could help choose the best treatment.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
Hear when a new Malignant Neoplasm of Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.